The annual survey of the Japanese Society for Dialysis Therapy Renal Data Registry (JRDR) was conducted with 4,512 dialysis facilities at the end of 2024, of which 4,447 facilities (98.6％) responded to the facility survey and 4,260 facilities (94.4％) responded to the patient survey. The increase in the number of dialysis patients in Japan has slowed in recent years. The number of dialysis patients at the end of 2024 was 337,414, which was a decrease from the previous year. The prevalence of dialysis patients was 2,725.4 per million population. The prevalent dialysis patients in the patient survey had a mean age of 70.27 years. Among these patients, diabetic nephropathy was the most common primary disease (39.2％), followed by chronic glomerulonephritis (23.0％) and nephrosclerosis (14.5％). The number of incident dialysis patients during 2024 was 36,404, which decreased by 2,360 from 2023. Among incident dialysis patients, the mean age was 71.69 years, and diabetic nephropathy (37.6％) was the most common cause of end-stage kidney disease, followed by nephrosclerosis (19.1％) and chronic glomerulonephritis (13.5％). The crude annual mortality rate was 11.3％, with 38,348 patients dying during 2024； this rate increased by last year. The three major causes of death were infectious disease (24.2％), which surpassed heart failure in 2024, heart failure (19.0％), and malignancy (7.4％). The number of patients treated by hemodiafiltration (HDF) has been rising since 2012, reaching 213,721 by the end of 2024 and accounting for 63.3％ of all dialysis patients. The number of peritoneal dialysis (PD) patients was 10,774 in 2024, which has slightly increased since 2017. Combination or hybrid therapy with hemodialysis (HD) or HDF was given to 21.1％ of PD patients. Home HD therapy was conducted in 767 patients as of the end of 2024； it decreased by 32 from 2023. In 2024, the patient survey newly included items investigating the types of antihypertensive medications used, the use and types of diuretics, the presence or absence of home blood pressure monitoring, lipid-related factors, and hepatitis virus‒related factors. Results obtained for each condition provide a framework to develop more clinically effective practice patterns for these conditions.